Lunaphore and abcam announce agreement for primary antibody validation for use on comet™, combining power of trusted antibody provider with superior multiplex capabilities

Lausanne, switzerland & cambridge, united kingdom--(business wire)-- #spatialbiology--lunaphore, a swiss life sciences company developing technology to enable spatial biology in every laboratory, and abcam (nasdaq: abcm), a global life science company working together with researchers to advance science and enable faster breakthroughs, today announced an agreement to co-market abcam primary antibodies specifically validated for use on lunaphore's comet™ platform.
ABCM Ratings Summary
ABCM Quant Ranking